SB's KYTRIL OVERCOMES UNFAVORABLE ADVISORY COMMITTEE REVIEW TO GET FDA APPROVAL AS FIRST-LINE CHEMO ADJUNCT; NOW IT FACES ENTRENCHED ZOFRAN IN MARKETPLACE
SmithKline Beecham's Kytril (granisetron) will enter the cancer anti-emetic market against an entrenched Glaxo product, Zofran (ondansetron) with two significant challenges: (1) the fallout from a skeptical advisory committee review of the product in mid-March; and (2) a probable declining price range in the category.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth